Fractional CFO for digital therapeutics companies

Digital therapeutics carry a hybrid economic profile: software product, drug-style economics, gated by FDA or EMA clearance and only viable once payers add it to formulary. Pear and Better both wound down post-clearance because covered lives never converted to prescription volume.

The CFO seat here is about defending runway across the gap between authorisation and reimbursement. That means tracking authorised prescriptions against actual claim adjudication and copay leakage, accruing chargebacks and rebates like a small specialty pharma, capitalising clinical and real-world evidence costs, and reconciling the gross-to-net spread PBMs apply to software. Board reporting centres on lives under coverage by payer type and cash burn between milestones.

Flow provides financial modelling, FP&A and fractional CFO advisory to digital therapeutics companies across prescription DTx operators, SaMD platforms, cardiometabolic and respiratory programmes, neurology and substance use therapeutics and OTC wellness adjuncts. Our startup CFO team brings the financial modelling discipline a DTx board needs across clearance, payer contracting and reimbursement.

Cannadorf
Cannabis Innovation Center
BiomX
TBô
Onlogist
Marcura
Hector
Bonart
Seagull Maritime
Moburst
Testim
Lemonade
Panorays
Percepto
Brew
Selina
BetterQA
Dataprana
Radtonics
Voereir
Cannadorf
Cannabis Innovation Center
BiomX
TBô
Onlogist
Marcura
Hector
Bonart
Seagull Maritime
Moburst
Testim
Lemonade
Panorays
Percepto
Brew
Selina
BetterQA
Dataprana
Radtonics
Voereir
Cannadorf
Cannabis Innovation Center
BiomX
TBô
Onlogist
Marcura
Hector
Bonart
Seagull Maritime
Moburst
Testim
Lemonade
Panorays
Percepto
Brew
Selina
BetterQA
Dataprana
Radtonics
Voereir

KPIs to track for "digital therapeutics" startups

We're very 'KPI-driven' fractional CFOs, and we make sure to monitor the right metrics for your startup.

Covered lives

Prescriptions written

Prescription fill rate

Net revenue per Rx

Payer contracts signed

Patient engagement rate

Clinical outcome delta

Adherence at 12 weeks

Gross margin

Cash runway

Financial modelling for "digital therapeutics" startups

As fractional CFOs, we build KPI-driven financial models that are insightful and easy to maintain.

Financial modelling is both art and science - models must be robust, but also understandable, and useful for both internal planning and VC fundraising purposes. Hire a fractional CFO who knows how to handle both sides of the equation.

Covered lives to net revenue funnel

Covered lives walked to prescriptions written, fills adjudicated and net revenue per Rx, with payer-by-payer conversion rates surfaced. The funnel that distinguishes formulary wins that monetise from formulary wins that stall.

Gross-to-net spread

List price stepped down through PBM rebates, payer-specific chargebacks, copay assistance and patient out-of-pocket to net revenue per fill. Accrued period by period rather than trued-up at year end, since DTx gross-to-net behaves like specialty pharma.

Clinical and RWE cost capitalisation

Clinical trial spend, real-world evidence studies and post-market commitments assessed against capitalisation criteria, with the rest expensed and tied to the runway model. The largest single judgement on the P&L between clearance and breakeven.

Payer contracting milestone model

Cash flow modelled against signed PBM contracts, formulary tier wins and J-code or NDC issuance, with the volume ramp each contract is expected to deliver. Ties commercial milestones to the runway envelope rather than treating them as commentary.

Runway and milestone-financed plan

Cash burn against the next clinical, regulatory and commercial milestone, with the financing requirement to reach each one explicit. The DTx category dies in the gap between clearance and reimbursement, and only a milestone-financed plan survives it.

Patient engagement to outcome economics

Engagement, adherence at 12 weeks and clinical outcome delta modelled against contract pricing tiers where outcome-based payment applies. Tells the board which payer deals genuinely pay for performance and which are de facto fee-for-prescription.

Recent fractional CFO track record

See our fractional CFO and financial modelling experience across digital therapeutics and beyond.

Simple pricing

No hidden costs, no complicated long-term contracts. We understand how important flexibility is for digital therapeutics startups.

Core£4,000

Per month

  • Accounting / FP&A tech stack implementation
  • Monthly financial statements and reporting pack
  • Quarterly board pack with detailed financial analysis (with variance analysis vs. budget, relevant KPI observations etc.)
  • Investor-friendly output
Grow£8,000

Per month

  • Everything in Core, plus
  • Operating model (via an online platform like Runway or Excel-based)
  • Ongoing model maintenance, refining projections, burn/runway management
  • Customer cohorts modelling, churn and retention analysis
  • LTV / CAC, unit economics analysis
  • Cap table management
Pro£12,000

Per month

  • Everything in Grow, plus
  • M&A / fundraising support; review of business plan
  • Pitch deck preparation
  • Investor approach strategy / list building
  • Due diligence support and deal negotiation
  • Valuation as required and free access to Multiples Pro

Packages shown are illustrative, final pricing is tailored to client requirements.

Explore our fractional CFO offering for similar verticals

We're a specialized fractional CFO to digital health companies.

Our fractional CFO experience spans across all digital health verticals.

SoftwareAI & MLFintechConsumer internetDigital mediaE-commerce & marketplacesConsumer productsMobilityIndustrial technologyDigital infrastructureIT services

More services

We help you scale by providing fractional CFO advice, through fundraising and a successful M&A exit.

VC fundraising for digital therapeutics companies

We help you prepare materials, reach out to investors in our extensive network, negotiate fair term sheets and structure the VC round.

Learn more

M&A for digital therapeutics companies

We advise winning tech companies on M&A exits, and over the years successfully executed numerous transactions with both financial and strategic buyers.

Learn more

Talk to us

Schedule a call to get a health check on your business and see how we could help.

Fractional CFO

Stages

Countries

Cities

Sectors

© 2026 Flow Partners (London) Ltd. All rights reserved. Registered as a limited liability company in England and Wales (registered number 12969521).